Pharmadrug (TSE:PHRX)
:PHRX
Top Page
Pharmadrug
(PHRX)
Select Model
Select Model
Rating:39Underperform
Price Target:
<C$0.01
▼(-55.00% Downside)
Action:DowngradedDate:02/03/26
The score is driven primarily by very weak financial performance (revenue collapse, ongoing losses, negative cash flow, and negative equity). Technicals also remain bearish with the stock trading below major moving averages and negative MACD. Valuation offers limited support due to negative earnings and no dividend yield.
Positive Factors
Regulatory and partnership focus
A strategic emphasis on regulatory pathways and evaluating assets/partnerships is a durable business-model lever. Successful regulatory progress or distribution partnerships can enable commercialization, de-risk R&D spend, and convert pipeline value into recurring revenue over the medium term.
Negative Factors
Revenue collapse to near zero
Sustained near-zero revenue across multiple years is a profound structural weakness: without recurring sales, the company cannot generate internal funding for R&D or commercialization. This undermines long-term viability and forces dependence on external financing or asset disposals.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory and partnership focus
A strategic emphasis on regulatory pathways and evaluating assets/partnerships is a durable business-model lever. Successful regulatory progress or distribution partnerships can enable commercialization, de-risk R&D spend, and convert pipeline value into recurring revenue over the medium term.
Read all positive factors
Pharmadrug (PHRX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.08M
Dividend YieldN/A
Average Volume (3M)101.80K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue GrowthN/A
EPS Growth98.93%
CountryCA
Employees9
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding108,234,380
10 Day Avg. Volume83,723
30 Day Avg. Volume101,798
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmadrug Business Overview & Revenue Model
Company Description
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It...
How the Company Makes Money
Pharmadrug makes money primarily through the sale and licensing of its pharmaceutical products. The company's revenue streams include direct sales of its therapies to healthcare providers, partnerships with other pharmaceutical firms for the co-de...
Pharmadrug Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 7.01K | 683.67K |
| Gross Profit | -50.24K | -50.24K | -26.22K | -2.26K | -2.15K | 182.04K |
| EBITDA | -133.04K | -549.04K | -1.33M | -2.34M | -4.21M | -4.28M |
| Net Income | -337.94K | -793.27K | -13.20M | -8.88M | -5.87M | -5.15M |
Balance Sheet | ||||||
| Total Assets | 578.37K | 711.80K | 1.20M | 12.11M | 19.52M | 13.69M |
| Cash, Cash Equivalents and Short-Term Investments | 17.72K | 75.04K | 423.06K | 329.24K | 1.30M | 4.40M |
| Total Debt | 1.43M | 1.35M | 1.77M | 1.42M | 866.37K | 1.13M |
| Total Liabilities | 2.00M | 1.96M | 2.66M | 3.28M | 2.66M | 3.12M |
| Stockholders Equity | -1.55M | -1.40M | -1.70M | 8.84M | 16.87M | 9.66M |
Cash Flow | ||||||
| Free Cash Flow | -80.92K | -768.60K | -671.88K | -2.26M | -4.17M | -1.43M |
| Operating Cash Flow | -80.92K | -756.62K | -671.88K | -2.26M | -4.13M | -1.41M |
| Investing Cash Flow | -11.98K | -11.98K | 995.04K | 77.58K | 1.48M | 3.78M |
| Financing Cash Flow | -4.44K | 321.56K | 225.51K | 843.25K | 776.97K | 132.24K |
Pharmadrug Technical Analysis
Negative
0.02
Price Trends
0.01
Negative
0.02
Negative
0.01
Negative
Market Momentum
>-0.01
Negative
44.58
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRX, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.58 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PHRX.
Pharmadrug Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$29.60M | -19.43 | -71.80% | ― | -3.94% | -17.62% | |
47 Neutral | C$16.74M | -4.56 | 899.59% | ― | ― | -80.42% | |
46 Neutral | C$17.62M | -1.56 | -461.32% | ― | -46.59% | 8.26% | |
45 Neutral | C$2.39M | -1.18 | -82.37% | ― | -15.51% | -49.26% | |
39 Underperform | C$1.08M | -3.51 | 16.08% | ― | ― | 98.93% | |
| ― | C$2.42M | -0.64 | ― | ― | 563.34% | -68.82% |
* Healthcare Sector Average
TSE:PHRX
Pharmadrug
0.01
0.00
0.00%
TSE:MVMD
Mountain Valley MD
0.05
0.02
66.67%
TSE:RVV
Revive Therapeutics
0.04
0.02
100.00%
TSE:INNO
InnoCan Pharma
6.58
-4.47
-40.45%
TSE:RAMM
Ramm Pharma
0.02
0.00
0.00%
TSE:AION
Aion Therapeutic Inc
0.01
0.00
0.00%
Pharmadrug Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
PharmaDrug Takes 19.9% Stake in Canurta and Restructures Capital to Advance Botanical Drug Portfolio
Positive
Jan 5, 2026
PharmaDrug has closed the first tranche of its acquisition of a 19.9% interest in Canurta Inc.’s parent entity, Canurta Limited Partnership, through the issuance of 25,980,000 common shares, and has added Canurta founder and CEO Akeem Gardne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.